Please login to the form below

Not currently logged in
Email:
Password:

Simbec appoints ex-ABPI DG as chairman

Trevor Jones move to the Wales-based CRO comes as Simbec receives a major cash boost

Trevor Jones, SimbecThe UK-based clinical research organisation (CRO) Simbec has named former ABPI director general Prof Trevor Jones as the company's new chairman.

Prof Jones joins Wales-based Simbec following a cash boost from the Wales Life Sciences Investment Fund – a £100m fund managed by Sir Chris Evans of Arthurian Life Sciences to support the life sciences industry in Wales.

Earlier this week, ReNeuron stated that the Fund was behind its move from England to Wales, and Sir Chris said that Simbec's appointment of Prof Jones was further evidence for its success.

“We are delighted that Prof Trevor Jones has agreed to be the new chairman of Simbec Research, which has a proven successful track record over 30 years in providing key clinical research expertise to global and UK based pharmaceutical and biotech companies,” said Sir Chris.

“This investment is a clear statement of the confidence we have in the future of Life Sciences in Wales.”

Prof Jones has a lengthy career in life sciences, including 20 years as R&D director at the Wellcome Foundation from 1987 to 1994.

Other senior roles include director general of the Association of the British Pharmaceutical Industry (ABPI) from 1994 to 2004, as well as numerous board roles at life science firms from 2004 to the present.

The most high profile of these include serving as a director at Allergan and chairman at Synexus.

Prof Jones has also served on many committees including the UK Government Medicines Commission, chair of the UK Genetics Advisory Board, the Council of King's College London an as a commissioner at the World Health Organization (WHO).

“It is a great pleasure to be joining Simbec with its established reputation for excellence in the efficient conduct of clinical trials for regulatory approvals,” he said.

“The clinical studies that Simbec performs are a pivotal component of the success of the pharmaceutical and biotech industry and we are well placed for future growth.”

24th July 2013

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Real Science Communications

Real Science Communications is a scientific centre of excellence, infusing credibility and scientific rigour into the conversations around health and...

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics